Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, Pharoah PD, Kommoss S, Jimenez-Linan M, Karlan BY, Gentry-Maharaj A, Menon U, Polo SH, Candido Dos Reis FJ, Doherty JA, Gayther SA, Sharma R, Larson MC, Harnett PR, Hatfield E, de Andrade JM, Nelson GS, Steed H, Schildkraut JM, Carney ME, Høgdall E, Whittemore AS, Widschwendter M, Kennedy CJ, Wang F, Wang Q, Wang C, Armasu SM, Daley F, Coulson P, Jones ME, Anglesio MS, Chow C, de Fazio A, García-Closas M, Brucker SY, Cybulski C, Harris HR, Hartkopf AD, Huzarski T, Jensen A, Lubiński J, Oszurek O, Benitez J, Mina F, Staebler A, Taran FA, Pasternak J, Talhouk A, Rossing MA, Hendley J; AOCS Group, Edwards RP, Fereday S, Modugno F, Ness RB, Sieh W, El-Bahrawy MA, Winham SJ, Lester J, Kjaer SK, Gronwald J, Sinn P, Fasching PA, Chang-Claude J, Moysich KB, Bowtell DD, Hernandez BY, Luk H, Behrens S, Shah M, Jung A, Ghatage P, Alsop J, Alsop K, García-Donas J, Thompson PJ, Swerdlow AJ, Karpinskyj C, Cazorla-Jiménez A, García MJ, Deen S, Wilkens LR, Palacios J, Berchuck A, Koziak JM, Brenton JD, Cook LS, Goode EL, Huntsman DG, Ramus SJ, Köbel M.

J Pathol Clin Res. 2018 Oct;4(4):250-261. doi: 10.1002/cjp2.109. Epub 2018 Sep 21.

2.

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE.

Br J Cancer. 2014 Dec 9;111(12):2297-307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30.

3.

DEF6 expression in ovarian carcinoma correlates with poor patient survival.

Liew PL, Fang CY, Lee YC, Lee YC, Chen CL, Chu JS.

Diagn Pathol. 2016 Aug 3;11(1):68. doi: 10.1186/s13000-016-0518-y.

4.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

5.

[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].

Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.

Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008. Chinese.

PMID:
29060967
6.

Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.

Darb-Esfahani S, Fritzsche F, Kristiansen G, Weichert W, Sehouli J, Braicu I, Dietel M, Denkert C.

Virchows Arch. 2012 Aug;461(2):109-16. doi: 10.1007/s00428-012-1273-4. Epub 2012 Jul 3.

PMID:
22752467
7.

Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.

Unger U, Denkert C, Braicu I, Sehouli J, Dietel M, Loibl S, Darb-Esfahani S.

Virchows Arch. 2017 Feb;470(2):143-151. doi: 10.1007/s00428-016-2050-6. Epub 2016 Dec 2.

PMID:
27913862
8.

Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.

Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ.

Int J Gynecol Pathol. 2011 May;30(3):205-17. doi: 10.1097/PGP.0b013e3182063e71.

PMID:
21464733
9.

Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma.

Phillips V, Kelly P, McCluggage WG.

Int J Gynecol Pathol. 2009 Mar;28(2):179-86. doi: 10.1097/PGP.0b013e318182c2d2.

PMID:
19188815
10.

Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.

Ferguson DC, Long DJ, Smith MC, Craig-Owens LD, Means J, Fadare O, Desouki MM.

J Ovarian Res. 2015 Jun 5;8:34. doi: 10.1186/s13048-015-0163-1.

11.

Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma.

Postovit LM, Dieters-Castator DZ, Rambau PF, Kelemen LE, Siegers GM, Lajoie GA, Köbel M.

Clin Cancer Res. 2019 Apr 12. pii: clincanres.3818.2018. doi: 10.1158/1078-0432.CCR-18-3818. [Epub ahead of print]

PMID:
30979743
12.

Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.

Liew PL, Hsu CS, Liu WM, Lee YC, Lee YC, Chen CL.

Int J Clin Exp Pathol. 2015 May 1;8(5):5642-9. eCollection 2015.

13.

Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.

Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B.

BMC Cancer. 2014 Feb 11;14:80. doi: 10.1186/1471-2407-14-80.

14.

APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.

Rüder U, Denkert C, Kunze CA, Jank P, Lindner J, Jöhrens K, Kulbe H, Sehouli J, Dietel M, Braicu E, Darb-Esfahani S.

Histol Histopathol. 2019 Apr;34(4):405-417. doi: 10.14670/HH-18-050. Epub 2018 Oct 5.

PMID:
30289149
15.

Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.

Rambau PF, McIntyre JB, Taylor J, Lee S, Ogilvie T, Sienko A, Morris D, Duggan MA, McCluggage WG, Köbel M.

Am J Surg Pathol. 2017 May;41(5):685-695. doi: 10.1097/PAS.0000000000000812.

PMID:
28125452
16.
17.

High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.

Assem H, Rambau PF, Lee S, Ogilvie T, Sienko A, Kelemen LE, Köbel M.

Am J Surg Pathol. 2018 Apr;42(4):534-544. doi: 10.1097/PAS.0000000000001016.

PMID:
29309296
18.

Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.

Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG.

Int J Gynecol Pathol. 2007 Jul;26(3):328-33.

PMID:
17581420
19.

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.

Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, Chu P, Nation JG, Karnezis AN, Han G, Kalloger SE, Köbel M.

Mod Pathol. 2013 Sep;26(9):1255-63. doi: 10.1038/modpathol.2013.55. Epub 2013 Apr 5.

20.

Histotype classification of ovarian carcinoma: A comparison of approaches.

Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA.

Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16.

PMID:
30121132

Supplemental Content

Support Center